about
Key roles of the OPG-RANK-RANKL system in bone oncologyIncreased osteoclastogenesis in mice lacking the carcinoembryonic antigen-related cell adhesion molecule 1Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis.Inhibition of bone resorption by econazole in rat osteoclast-like cells through suppressing TRPV5.RANK, RANKL and OPG Expression in Breast Cancer - Influence on Osseous Metastasis.Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progressionTreatment of malignant hypercalcaemia.Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia.Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genisteinThe influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysisBone-invasive oral squamous cell carcinoma in cats: pathology and expression of parathyroid hormone-related protein.Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.A tale of mice and (wo)men: development of and insights from an "all human" animal model of breast cancer metastasis to boneRANKL/RANK/OPG: key therapeutic target in bone oncology.Therapeutic implications of osteoprotegerin.Bone metastasis in a novel breast cancer mouse model containing human breast and human bone.Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligandVascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand.Dihydroartemisinin, an Anti-Malaria Drug, Suppresses Estrogen Deficiency-Induced Osteoporosis, Osteoclast Formation, and RANKL-Induced Signaling Pathways.
P2860
Q28287394-EB66B243-EB25-46DD-81D0-1AB29C24834AQ28513481-8F429E75-2B46-4645-B1C9-057642558C96Q33772382-F4066D0C-0CB9-4008-91A2-4E7B3F1F4AB5Q33949704-6FDFC126-0602-4A81-9AE4-2BE94A4DEEE9Q34209272-22D93900-8FD7-4A7B-A5AC-82108FD072C7Q34394070-F6181B01-012C-4712-B36B-D01A70EAF74BQ34628598-1CB562F7-6531-47E9-8F7C-6FB6ACCDA029Q34764949-E8C17988-01A8-4400-830F-B2395A5B88E4Q34770095-64F5358F-D353-49DF-8CE8-3D6F825E085AQ35611123-D89441CE-7EF0-49B9-BC2C-370FE80B593FQ35843398-CB24A64C-748A-4ED6-BE45-5909563AF613Q35900360-09B6D8DA-EBBE-4C17-99D4-2D5477ABC6E4Q36072569-969590AF-F0D2-4234-96A4-A7FAABC0DB3AQ36519704-A2F38503-F69E-4407-A291-3F077C029FBEQ37140665-CAD1E53B-88B5-4C7D-BC47-06E539177DC1Q37368570-DE8CAF66-1FA6-4E67-B811-331E28A43D29Q39531184-F1BB01E9-C4AB-41A7-9C1F-3AD5C961DAFCQ41497465-F7442A59-5844-4B61-B61C-3FF647BFC4B7Q41712371-4949C4F5-8729-425B-8AEE-7EFFC837F993Q42834177-6FDE6F20-7F27-4A4C-904C-AC993C1861FCQ44534331-0B4D9E78-67A6-4DEF-AE67-D4EEC6A94B73Q47940565-66B6D46D-56BD-4A8C-8319-6E1391B66391
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Osteolysis and cancer.
@en
Osteolysis and cancer.
@nl
type
label
Osteolysis and cancer.
@en
Osteolysis and cancer.
@nl
prefLabel
Osteolysis and cancer.
@en
Osteolysis and cancer.
@nl
P2860
P356
P1476
Osteolysis and cancer.
@en
P2093
Goltzman D
P2860
P304
P356
10.1172/JCI13073
P407
P577
2001-05-01T00:00:00Z